A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
Open Access
- 12 January 2012
- journal article
- review article
- Published by Hindawi Limited in Dermatology Research and Practice
- Vol. 2012, 1-7
- https://doi.org/10.1155/2012/260643
Abstract
Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body fluids such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum biomarkers of melanoma progression and metastatic disease are still awaited in order to provide efficient rationale for followup and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma patients. However, the poor sensitivity and specificity of those markers and many other molecules are serious limitations for their routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology and proteomic research will surely provide new candidates in the near future allowing more accurate definition of the individual prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies.Keywords
This publication has 16 references indexed in Scilit:
- Elevated MIA levels in the serum of pregnant women and of childrenClinical and Experimental Dermatology, 2004
- Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenaseBritish Journal of Cancer, 2004
- Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanomaMelanoma Research, 2003
- Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patientsEuropean Journal of Cancer, 2002
- Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)?Melanoma Research, 2001
- A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma.2001
- MART-1 Is Expressed Less Frequently on Circulating Melanoma Cells in Patients Who Develop Distant Compared With Locoregional MetastasesJournal of Clinical Oncology, 1999
- S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV MelanomaJournal of Clinical Oncology, 1999
- Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patientsMelanoma Research, 1999
- Tyrosinase activity in the serum of patients with malignant melanomaMelanoma Research, 1995